A nitrogen-containing ring derivative regulator, a preparation method therefor and use thereof. In particular, the present invention relates to a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof as a G protein-coupled receptor regulator in the treatment or prevention of central nervous system diseases and/or mental diseases.

##STR00001##

The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.

The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.

A small molecule compound of a NO donor is a compound shown in the following structural formula I or a stereoisomer, a geometric isomer, a tautomer, a racemate, a deuterated isotopic derivative, a hydrate, a solvate, a metabolite, or a pharmaceutically acceptable salt or prodrug thereof;

##STR00001##

wherein a ring A is a substituted or unsubstituted heteroaromatic ring; X is selected from (CH.sub.2); R is a substituent of terminal —O—NO2; R.sup.1 is selected from hydrogen, a hydroxyl group, a halogen, an amino group, a cyano group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, or a substituted or unsubstituted heteroalkyl group; R.sup.2 and R.sup.3 are each independently selected from hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, or an amino protecting group.

A small molecule compound of a NO donor is a compound shown in the following structural formula I or a stereoisomer, a geometric isomer, a tautomer, a racemate, a deuterated isotopic derivative, a hydrate, a solvate, a metabolite, or a pharmaceutically acceptable salt or prodrug thereof;

##STR00001##

wherein a ring A is a substituted or unsubstituted heteroaromatic ring; X is selected from (CH.sub.2); R is a substituent of terminal —O—NO2; R.sup.1 is selected from hydrogen, a hydroxyl group, a halogen, an amino group, a cyano group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, or a substituted or unsubstituted heteroalkyl group; R.sup.2 and R.sup.3 are each independently selected from hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, or an amino protecting group.

This disclosure relates to synthetic coupling methods using catalytic molecules. In certain embodiments, the catalytic molecules comprise heterocyclic thiolamide, S-acylthiosalicylamide, disulfide, selenium containing heterocycle, diselenide compound, ditelluride compound or tellurium containing heterocycle. Catalytic molecules disclosed herein are useful as catalysts in the transformation of hydroxy group containing compounds to amides, esters, ketones, and other carbon to heteroatom or carbon to carbon transformations

This disclosure relates to synthetic coupling methods using catalytic molecules. In certain embodiments, the catalytic molecules comprise heterocyclic thiolamide, S-acylthiosalicylamide, disulfide, selenium containing heterocycle, diselenide compound, ditelluride compound or tellurium containing heterocycle. Catalytic molecules disclosed herein are useful as catalysts in the transformation of hydroxy group containing compounds to amides, esters, ketones, and other carbon to heteroatom or carbon to carbon transformations

A compound represented by formula (I) or formula (II) has a pest control effect. (In the formulae, Q.sup.1 represents a pyrazine ring or the like; G.sup.1 represents a nitrogen atom or a carbon atom; X.sup.1 represents an alkyl group or the like; m represents the number of X.sup.1 moieties; A represents an oxygen atom or the like; Y represents a single bond or the like; Q.sup.2 represents a benzene ring or the like; X.sup.2 represents an alkyl group, an aryl group or the like; X.sup.3 represents a halogeno group or the like; n represents the number of X.sup.3 moieties; Z.sup.q- represents a counter ion; and q represents 1 or 2.)

##STR00001##

This invention provides a method of ameliorating the symptoms of, or treating a neurodegenerative disorder, Welander distal myopathy, psychiatric illness, or cancer in a mammal, the method comprising administering to the mammal an effective amount of a compound that decreases TIA1-dependent stress granule formation.

This invention provides a method of ameliorating the symptoms of, or treating a neurodegenerative disorder, Welander distal myopathy, psychiatric illness, or cancer in a mammal, the method comprising administering to the mammal an effective amount of a compound that decreases TIA1-dependent stress granule formation.